220.127.116.11. Intra-uterine progestogen-only device
|1st choice||Kyleena® 19.5mg intrauterine device||Dose:|
Insert into uterine cavity within 7 days of the onset of menstruation (anytime if replacement); effective for 5 years
|Mirena® 20 micrograms/24 hours intrauterine delivery system||Dose:|
Insert tube into uterine cavity within 7 days of the onset of menstruation (anytime if replacement); effective for 5 years
- Refer to NICE Guidance CG 30 Long Acting Reversible Contraception and FSRH guidance.
- Levonorgestrel-releasing intrauterine systems should always be prescribed by brand name, see MHRA guidance.
- IUS insertions should be performed by trained healthcare staff who are regularly updated and who perform frequent insertions (recommendation is 12 or more per year).
- Levonorgestrel intrauterine system products are highly effective methods of contraception.
- Kyleena® has a lower levonorgestrel content. Unlike Mirena®, it is not licensed for the management of heavy menstrual bleeding or to provide endometrial protection as part of HRT. It has been suggested that a narrower introducer and smaller device could make Kyleena® more suitable for nulliparous or young women.
- Many women experience quite frequent and prolonged spotting for the first 3–6 months, thereafter amenorrhoea is common. Patients should be counselled accordingly.
- Mirena® has a beneficial effect on dysmenorrhoea and menorrhagia.